Helen Volokhonsky, MD
Geriatric Medicine · Philadelphia, PANPI 1285675009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $607 and has fallen 76.4% since, to $143 in 2025.
Across 81 payments — averaging $34.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$658
- AstraZeneca$536
- Lilly USA, LLC$498
- Sanofi-aventis U.S. LLC$267
- AbbVie$166
- Abbott$132
- plus $516 from 16 others
What the payments were for
- Food & beverage$2,773100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $658 |
| AstraZeneca | 7 | $536 |
| Lilly USA, LLC | 11 | $498 |
| Sanofi-aventis U.S. LLC | 2 | $267 |
| AbbVie | 9 | $166 |
| Abbott | 7 | $132 |
| Astellas Pharma US Inc | 4 | $81 |
| Merck | 5 | $64 |
| Amarin Pharma, Inc. | 2 | $45 |
| GSK | 3 | $42 |
| Novartis | 3 | $40 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Boehringer Ingelheim | 2 | $32 |
| Exact Sciences | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Pfizer | 1 | $15 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,773 in reported general payments places this provider in the 85th percentile of 217 geriatric medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 104 | $58,502 |
| OzempicSemaglutide | 48 | $43,026 |
| VascepaIcosapent Ethyl | 84 | $28,545 |
| EliquisApixaban | 32 | $24,103 |
| CreonLipase/Protease/Amylase | 24 | $17,956 |
| FarxigaDapagliflozin Propanediol | 18 | $16,666 |
| ZenpepLipase/Protease/Amylase | 13 | $16,154 |
| Dexlansoprazole DrDexlansoprazole | 78 | $14,829 |
| MyrbetriqMirabegron | 26 | $14,598 |
| TradjentaLinagliptin | 18 | $13,339 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $12,513 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $11,104 |
| JardianceEmpagliflozin | 13 | $9,607 |
| AmbienZolpidem Tartrate | 14 | $9,051 |
| JanuviaSitagliptin Phosphate | 17 | $8,992 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Restasis, Synthroid | $166 | $85,931182 claims |
| Novo NordiskOzempic | $658 | $43,02648 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta | $42 | $31,55667 claims |
| PfizerEliquis | $15 | $24,10332 claims |
| Boehringer IngelheimTradjenta, Jardiance | $32 | $22,94531 claims |
| AstraZenecaFarxiga, Symbicort | $536 | $21,15437 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $14,59826 claims |
| Sanofi-aventis U.S. LLCAmbien | $267 | $9,05114 claims |
| MerckJanuvia | $64 | $8,99217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 217 geriatric medicine providers in Pennsylvania.
Other geriatric medicine in Philadelphia
- Richard StefanacciPhiladelphia$146K
- Michele ZaworaPhiladelphia$21K
- Jason KarlawishPhiladelphia$11K
- Ellen ZagrebelskyPhiladelphia$7K
- Katherine GalluzziPhiladelphia$7K
- Vladimir ZagrebelskyPhiladelphia$6K
- Lesley CarsonPhiladelphia$3K
- Jerry JohnsonPhiladelphia$2K
- Nicol JosephPhiladelphia$528
- James LinErie$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.